Venetoclax and Obinutuzumab in CLL

Mazyar Shadman, MD, MPH, explains the safety and efficacy of fixed-duration venetoclax-based therapy for initial treatment of chronic lymphocytic leukemia in this panel discussion moderated by William Wierda, MD, PhD.
Website: www.onclive.com
Twitter: / onclive
Facebook: / onclive
LinkedIn: / onclive